Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome

Ophthalmic Research

Volumn 55, Issue 1, 2015, Pages 10-18

  Farinha, Cláudia ^a,b   Marques, João Pedro ^a   Almeida, Elisabete ^a   Baltar, Alda ^a   Santos, Ana Rita ^b   Melo, Pedro ^b   Costa, Miguel ^b   Figueira, João ^a,b,c   Cachulo, Maria Luz ^a,b,c   Pires, Isabel ^a,b   Silva, Rufino ^a,b,c  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Fluorescein angiography; Macular edema; Optical coherence tomography; Retinal vein occlusion; Vascular endothelial growth factor; Visual acuity

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MACULAR EDEMA; MALE; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION;

AGED; ANGIOGENESIS INHIBITORS; CROSS-SECTIONAL STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84946731536     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000440848     Document Type: Article

References (29)

1. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, Do DV, Solomon S, Sodhi A, Gehlbach P, Duh E, Baranano D, Campochiaro PA: Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol 2013; 156: 693-705.
2. Rehak M, Wiedemann P: Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010; 8: 1886-1894.
3. Duker JS, Brown GC: Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol 1989; 107: 998-1000.
4. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D: Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982; 100: 1132-1140.
5. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, Mones J, de Smet M, Soubrane G, Staurenghi G: Management of retinal vein occlusion-consensus document. Ophthalmologica 2011; 226: 4-28.
6. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791-799.
7. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.
8. Hahn P, Fekrat S: Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 2012; 23: 175-181.
9. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
10. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133.
11. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602.
12. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
13. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014; 121: 209-219.
14. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I: Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010; 150: 310-314.
15. Chang LK, Spaide RF, Klancnik JM, Sorenson J, Slakter JS, Freund KB, Yannuzzi LA, Tseng JJ, Klein R: Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 2011; 31: 821-828.
16. Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, Wong WL, Wong TY: Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 2014; 157: 237-247.
17. Lotery AJ, Regnier S: Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye (Lond) 2015; 29: 380-387.
18. Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW: Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 2014; 8: 1611-1621.
19. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG: Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2013; 120: 795-802.
20. Manousaridis K, Talks J: Macular ischaemia: A contraindication for anti-VEGF treatment in retinal vascular disease? Br J Ophthalmol 2012; 96: 179-184.
21. Feucht N, Schonbach EM, Lanzl I, Kotliar K, Lohmann CP, Maier M: Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. Clin Ophthalmol 2013; 7: 173-178.
22. Tsuiki E, Suzuma K, Ueki R, Maekawa Y, Kitaoka T: Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion. Am J Ophthalmol 2013; 156: 543-547.
23. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S: Subfoveal choroidal thickness after ranibizumab therapy for neovascular agerelated macular degeneration: 12-month results. Ophthalmology 2012; 119: 1621-1627.
24. Marques JP, Costa M, Melo P, Oliveira CM, Pires I, Cachulo ML, Figueira J, Silva R: Ocular risk factors for exudative AMD: A novel semiautomated grading system. ISRN Ophthalmol 2013; 2013: 464218.
25. Spaide RF, Koizumi H, Pozzoni MC: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146: 496-500.
26. Margolis R, Spaide RF: A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009; 147: 811-815.
27. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114.
28. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128.
29. Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL; RAVE Study Group: Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina 2014; 34: 1728-1735.